Xenetic and Santersus Combine to Build a Nasdaq Company Targeting Neutrophil Extracellular Traps
NucleoCapture and DNase will target NETs in sepsis, lupus, transplant and lymphoma.
/ 491 items
#XY Event-Driven Stocks↓
Needham Upgrades Rocket Pharmaceuticals After FDA Clears Path for Danon Gene Therapy Trial
FDA let Rocket keep its 12-patient Danon study and count the first 3 patients. Needham upgraded RCKT and removed a key regulatory overhang.
Tempest Adds Second In-Vivo CAR-T Approach with Senlang Deal
Tempest gets an exclusive option to license Senlang’s CD7-targeted lentiviral in-vivo CAR-T, now in Phase 1 for relapsed multiple myeloma.
Ascendis Pharma Stock Drops After Ending Novo Partnership
Ascendis will develop TransCon obesity and cardiometabolic programs itself after ending its Novo collaboration and starting a $400M buyback.
GTBP’s Myeloma Headline Was Weaker Than It Sounded
FDA cleared a grant-dependent myeloma IND for GTB-5550. Cheap preferred, 100% warrants, and a tiny float explain the selloff.
Alignment Healthcare Slides After Conference Comments on Stars, Costs, and Ratings Uncertainty
Management cited Star-rating limits, HEI frustration, and a small cost rise.